Circular RNA circPSAP functions as an efficient miR-331-3p sponge to regulate proliferation, apoptosis and bortezomib sensitivity of human multiple myeloma cells by upregulating HDAC4.

[1]  R. Orlowski,et al.  Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat , 2021, Cancer drug resistance.

[2]  Nianhu Li,et al.  Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related peripheral neuropathy. , 2020, Cellular signalling.

[3]  Rashmi Kumar,et al.  Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  A. Goodman,et al.  Persistent Challenges with Treating Multiple Myeloma Early. , 2020, Blood.

[5]  Xiaojie Li,et al.  Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis , 2020, Cell cycle.

[6]  Yan-Li Wang,et al.  Upregulation of circ_0000142 promotes multiple myeloma progression by adsorbing miR-610 and upregulating AKT3 expression. , 2020, Journal of biochemistry.

[7]  Yunfei Xu,et al.  circPTCH1 promotes invasion and metastasis in renal cell carcinoma via regulating miR-485-5p/MMP14 axis , 2020, Theranostics.

[8]  Yanwei Luo,et al.  Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma , 2020, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[9]  M. Gorospe,et al.  Circular RNAs in Blood Malignancies , 2020, Frontiers in Molecular Biosciences.

[10]  C. Luo,et al.  BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis , 2020, Therapeutic advances in hematology.

[11]  Qingyuan Yang,et al.  MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4 , 2020, Autophagy.

[12]  Ming-chuan Zhao,et al.  miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2 , 2020, Technology in cancer research & treatment.

[13]  H. Fan,et al.  circRNA_0000140 suppresses oral squamous cell carcinoma growth and metastasis by targeting miR-31 to inhibit Hippo signaling pathway , 2020, Cell Death & Disease.

[14]  Y. Yang,et al.  Long noncoding RNA UCA1 regulates proliferation and apoptosis in multiple myeloma by targeting miR-331-3p/IL6R axis for the activation of JAK2/STAT3 pathway. , 2019, European review for medical and pharmacological sciences.

[15]  Hongye Zhang,et al.  miR-331-3p suppresses cell invasion and migration in colorectal carcinoma by directly targeting NRP2 , 2019, Oncology letters.

[16]  H. Handa,et al.  The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma , 2019, Cancers.

[17]  S. Pfeffer,et al.  HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway , 2019, Cancers.

[18]  Wei Wei,et al.  Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma , 2019, BMC Cancer.

[19]  Jørgen Kjems,et al.  The biogenesis, biology and characterization of circular RNAs , 2019, Nature Reviews Genetics.

[20]  N. Munshi,et al.  The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma , 2019, Leukemia.

[21]  Ping Liu,et al.  Histone deacetylase inhibitor LMK‐235‐mediated HO‐1 expression induces apoptosis in multiple myeloma cells via the JNK/AP‐1 signaling pathway , 2019, Life sciences.

[22]  F. Davies,et al.  Toward personalized treatment in multiple myeloma based on molecular characteristics. , 2019, Blood.

[23]  G. Pan,et al.  CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway , 2019, Journal of experimental & clinical cancer research : CR.

[24]  Wei-Min Chen,et al.  [Effect of Expression Levels of MiRNA-132, -125, -143 and -145 on Autophagy and Apoptosis of Multiple Myeloma Cells]. , 2018, Zhongguo shi yan xue ye xue za zhi.

[25]  Jian Li,et al.  Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells. , 2018, International journal of oncology.

[26]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[27]  S. S. Koh,et al.  STAT1-HDAC4 signaling induces epithelial-mesenchymal transition and sphere formation of cancer cells overexpressing the oncogene, CUG2 , 2018, Oncology reports.

[28]  Zhongxin Lu,et al.  miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer , 2018, Carcinogenesis.

[29]  Hong Chang,et al.  Role of epigenetics-microRNA axis in drug resistance of multiple myeloma , 2017, Journal of Hematology & Oncology.

[30]  N. Munshi,et al.  Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. , 2016, Molecular cancer therapeutics.

[31]  Y. Tomari,et al.  The Functions of MicroRNAs: mRNA Decay and Translational Repression. , 2015, Trends in cell biology.

[32]  A. Ghafoor,et al.  Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. , 2015, The Journal of molecular diagnostics : JMD.

[33]  P. L. Bergsagel,et al.  Transcriptional repression by the HDAC4–RelB–p52 complex regulates multiple myeloma survival and growth , 2015, Nature Communications.

[34]  P. Richardson,et al.  Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma , 2015, Leukemia.

[35]  K. Lakshmaiah,et al.  Epigenetic therapy of cancer with histone deacetylase inhibitors. , 2014, Journal of cancer research and therapeutics.

[36]  Lei Wang,et al.  Histone Deacetylase HDAC4 Promotes Gastric Cancer SGC-7901 Cells Progression via p21 Repression , 2014, PloS one.

[37]  Eman M Sewify,et al.  Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression. , 2014, Clinical lymphoma, myeloma & leukemia.

[38]  P. Tassone,et al.  Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma , 2013, Expert opinion on biological therapy.

[39]  Sebastian D. Mackowiak,et al.  Circular RNAs are a large class of animal RNAs with regulatory potency , 2013, Nature.

[40]  Junmin Chen,et al.  Knockdown of c‐Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[41]  Chris T. Harvey,et al.  HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia* , 2011, The Journal of Biological Chemistry.

[42]  Euan A Stronach,et al.  HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. , 2011, Cancer research.

[43]  Kuo-I Lin,et al.  Involvement of Histone Demethylase LSD1 in Blimp-1-Mediated Gene Repression during Plasma Cell Differentiation , 2009, Molecular and Cellular Biology.

[44]  Andrew J. Wilson,et al.  HDAC4 promotes growth of colon cancer cells via repression of p21. , 2008, Molecular biology of the cell.

[45]  T. Harada.  [Role of HDAC isoforms and development of treatment of multiple myeloma using isoform-specific HDAC inhibitors]. , 2019, [Rinsho ketsueki] The Japanese journal of clinical hematology.